Name of opportunity: 👀
Viking Therapeutics, Inc
Triple whammy ⚂
In their third quarter earnings call, Viking Therapeutics gave further information about a widely anticipated new weight loss drug the company is developing, which will target the amylin and calcitonin hormone receptors.
Right now, Eli Lilly’s Mounjaro also sold under the name Zepbound is a big name drug because it is a dual agonist, but that company is also developing a triagonist drug that will target three receptors.
Viking Therapeutics has indicated a plan to combine its new treatment with existing pharmaceutical technology, to make a drug with a highly sophisticated quadruple mechanism. This might give Viking an advantage over its competitors, as the more pathways a drug targets, it might have increased efficacy.
How hot is this investment opportunity? 🔥🔥🔥
Analysts predict the price of Viking Therapeutics, Inc. might increase from $58.03 to $114.20 in the next 12 months. If you invested $1000, you might profit $901.43.
While the stock reached $80.60 on 25 October, it has since dropped to $58.03. One reason for Viking’s volatility might be that the company does not yet have an FDA approved drug, as all its medicines are still in development. But in the earnings report, Viking shared positive data from four clinical programs, including drugs for weight loss and liver conditions. The company also has $930 million in cash and equivalents, despite its high (and growing) expenses.
Tomorrow's medicines: 🩺
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. It was founded in 2012 and went public in 2015. Viking is based in California, US.
Which neme?: 🔍
‘Biggest Losers Today’, ‘Stocks On The Move’
Download Nemo Money to check out Viking Therapeutics - new users can grab our registration bonus. We’ll give you 50% of the first $50 you top up with (or 50% of any amount up to that).
